The Southern Nevada Cancer Research Foundation (SNCRF) was established to conduct cancer research under the Community Clinical Oncology Program structure. The long term objectives are to continue to increase the number of local patients put on national study protocols thus aiding these studies in answering questions critical to the treatment of cancer.
SNCRF aims to make available to cancer patients the broadest and most appropriate recent therapies for their cancer; in a more timely fashion than waiting for it to become standard therapy. SNCRF plans to become extensively involved in cancer control activities designed to answer scientific questions about the effectiveness of these activities. This will become a major thrust of the CCOP over the next several years. SNCRF will use these avenues of treatment and cancer control protocols to improve the quality of cancer care in the community. As well, this work will contribute to the efforts to control cancer both locally and nationally.
SNCRF aims to use the CCOP mechanism as an educational tool. It will educate both lay and professional personnel as to the efforts and successes of both local and national efforts in cancer therapy and cancer control. The methods for accomplishing these goals will be through application of the CCOP grant monies. National study protocols developed by or in cooperation with national cooperative groups will be used both to treat the patients and to answer cancer control questions. SNCRF has proposed ideas for cancer control protocols and will utilize the ones developed by the groups it belongs to: CALGB, NSABP, RTOG, CCSG and UC San Diego.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035421-09
Application #
3557759
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-30
Project End
1994-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Southern Nevada Cancer Research Fdn
Department
Type
DUNS #
173852054
City
Las Vegas
State
NV
Country
United States
Zip Code
89106
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48

Showing the most recent 10 out of 59 publications